Literature DB >> 3549617

Electron microscopy and HLA expression of a new cell line of retinoblastoma.

G A Fournier, D N Sang, D M Albert, J L Craft.   

Abstract

A new continuous retinoblastoma cell line (Rb 355-7) derived from a nonfamilial unilaterally-affected child was studied morphologically and with regard to HLA expression. The tumor was compared with two older and widely studied cell lines, the Y-79 and WERI-Rb1 strains. The Rb 355-7 line grew in tissue culture in clusters and chains. Its doubling time was calculated to be 4.4 days. In contrast to the Y-79 and WERI-Rb1 cell lines, the Rb 355-7 showed a paucity of HLA expression.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3549617

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  4 in total

1.  Revisiting old drugs as novel agents for retinoblastoma: in vitro and in vivo antitumor activity of cardenolides.

Authors:  Christophe Antczak; Carolyn Kloepping; Constantin Radu; Thorsten Genski; Lutz Müller-Kuhrt; Karsten Siems; Elisa de Stanchina; David H Abramson; Hakim Djaballah
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-01-17       Impact factor: 4.799

2.  Invasiveness and metastasis of retinoblastoma in an orthotopic zebrafish tumor model.

Authors:  Xiaoyun Chen; Jian Wang; Ziquan Cao; Kayoko Hosaka; Lasse Jensen; Huasheng Yang; Yuping Sun; Rujie Zhuang; Yizhi Liu; Yihai Cao
Journal:  Sci Rep       Date:  2015-07-14       Impact factor: 4.379

Review 3.  Heterogeneity in retinoblastoma: a tale of molecules and models.

Authors:  Sonya Stenfelt; Maria K E Blixt; Charlotta All-Ericsson; Finn Hallböök; Henrik Boije
Journal:  Clin Transl Med       Date:  2017-11-09

4.  A synergetic screening approach with companion effector for combination therapy: application to retinoblastoma.

Authors:  Jeni P Mahida; Christophe Antczak; Daniel Decarlo; Kathryn G Champ; Jasmine H Francis; Brian Marr; Arthur S Polans; Daniel M Albert; David H Abramson; Hakim Djaballah
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.